LEAP2 in Physiology—A Narrative Review
International Journal of Molecular Sciences · 04.01.2025 · 26 (1) · 377
DOI: 10.3390/ijms26010377 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.01.2025. Verfasst von Oskar Sosinski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Wolynska 35 Street, 60-637 Poznan, Poland. Hauptthemen laut MEDLINE: Energy Metabolism, Diabetes Mellitus, Type 2, Ghrelin, Obesity. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center Poland, 2021/41/B/NZ5/00446, Department of Animal Physiology, Biochemistry, and Biostructure at the Faculty of Veterinary Medicine and Animal Science, Poznan University of Life Sciences, P….
Abstract (Originalsprache)
Liver Enriched Antimicrobial Peptide 2 (LEAP2) is a fascinating peptide that has gained significant attention since its discovery in 2003. Initially identified as an antimicrobial peptide, LEAP2 has more recently been found to play a key role in the regulation of energy metabolism. One of the most notable functions of LEAP2 is its interaction with the ghrelin hormone, which is known for stimulating hunger. LEAP2 acts as an inhibitor of ghrelin, thereby reducing food intake and influencing energy balance. The physiological roles of LEAP2 extend beyond appetite suppression. Studies have shown that LEAP2 has an impact on insulin secretion, suggesting its potential involvement in glucose metabolism and possibly insulin sensitivity, which is crucial in managing conditions like type 2 diabetes. Moreover, LEAP2 levels appear to fluctuate based on factors such as gender, developmental stage, and even interventions like bariatric surgery, which is known for its role in managing obesity and diabetes. Given these findings, LEAP2 shows potential as a therapeutic target, particularly for addressing obesity and metabolic diseases such as type 2 diabetes. Its ability to influence food intake and energy balance makes it a promising candidate for further research into therapies aimed at weight regulation and glycemic control. In the future, LEAP2 could become an important agent in the development of treatments aimed at curbing obesity and its associated metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Wolynska 35 Street, 60-637 Poznan, Poland.
ORCID-Profile: Ewa Pruszynska-Oszmalek, Natalia Leciejewska, Pawel Antoni Kolodziejski
Förderung
- National Science Center Poland
- 2021/41/B/NZ5/00446
- Department of Animal Physiology, Biochemistry, and Biostructure at the Faculty of Veterinary Medicine and Animal Science, Poznan University of Life Sciences, P…
- Polish Minister of Science and Higher Education
Zitieren
APA
Sosinski, O., Pruszynska-Oszmalek, E., Leciejewska, N., Sassek, M., & Kolodziejski, P. A. (2025). LEAP2 in Physiology—A Narrative Review. International Journal of Molecular Sciences, 26(1), 377. https://doi.org/10.3390/ijms26010377
Vancouver
Sosinski O, Pruszynska-Oszmalek E, Leciejewska N, Sassek M, Kolodziejski PA. LEAP2 in Physiology—A Narrative Review. International Journal of Molecular Sciences. 2025;26(1):377. doi:10.3390/ijms26010377
BibTeX
@article{Sosinski2025,
author = {Sosinski, Oskar and Pruszynska-Oszmalek, Ewa and Leciejewska, Natalia and Sassek, Maciej and Kolodziejski, Pawel Antoni},
title = {LEAP2 in Physiology—A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {1},
pages = {377},
doi = {10.3390/ijms26010377}
}
EUVIMED